Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in Multiple myeloma patients?

European Journal of Haematology

Volumn 92, Issue 1, 2014, Pages 13-18

  Bedewy, Ahmed M L ^a   El Maghraby, Shereen M ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cereblon; Interleukin 6 receptor; Multiple myeloma; Thalidomide

Indexed keywords

BETA 2 MICROGLOBULIN; CEREBLON PROTEIN; DEXAMETHASONE; INTERLEUKIN 6 RECEPTOR; PROTEIN; SERUM ALBUMIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

CEREBLON; INTERLEUKIN-6 RECEPTOR; MULTIPLE MYELOMA; THALIDOMIDE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; DEXAMETHASONE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-6; SYNDECAN-1; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84890191125     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12207     Document Type: Article

References (23)

1. Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res 2013;19:3337-44.
2. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30.
3. Dijkhuizen T, van Essen T, van der Vlies P, Verheij JB, Sikkema-Raddatz B, van der Veen AY, Gerssen-Schoorl KB, Buys CH, Kok K. FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to mental retardation in 3pter deletions. Am J Med Genet A 2006;140:2482-7.
4. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-50.
5. Chang X, Stewart K. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2011;2:287-94.
6. Girona A, Mendy D, Ito T, et al. Cereblon is a direct Protein target for immunomodulatory and anti-Proliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2326-35.
7. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013;54:683-7.
8. Rose-John S. Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv Exp Med Biol 2001;495:145-51.
9. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992;4:96-100.
10. Campo E, Swerdlow S, Harris N, Pileri S, Stein H. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32.
11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
12. Dispenzieri A, Lacy M, Greipp P. Multiple myeloma. In: Greer J, Foerster J, Rodgers G, et al., eds. Wintrobe's Clinical Hematology, 12th edn. Philadelphia: Lippincott Williams & Wilkins; 2009:2373-439.
13. Durie BGM, Harousseau JL, Miguel JS, Blade' J, Barlogie B, Anderson K. International uniform response criteria for Multiple myeloma. Leukemia 2006;20:1467-73.
14. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9.
15. -{increment}{increment}CT method. Methods 2001;25:402-8.
16. Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161:695-700.
17. Broyl A, Kuiper R, van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013;121:624-7.
18. Klimowicz A, Neri P, Belch A, et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood (ASH Annual Meeting Abstracts) 2012;120:931.
19. Safra I, Ladeb S, Skouri N, et al. Does multiple myeloma response induction therapy depending on plasma cell il6 receptor gene expression. Tunis Med 2013;91:337-41.
20. Kim SY, Min HJ, Park HK, et al. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:810-20.
21. Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-4.
22. Thabard W, Barillé S, Collette M, Harousseau JL, Rapp MJ, Bataille R, Amiot M. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. Clin Cancer Res 1999;5:2693-7.
23. Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012;119:503-12.